FY2024 EPS Estimates for Neurogene Cut by William Blair

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at William Blair reduced their FY2024 earnings estimates for Neurogene in a research note issued to investors on Tuesday, November 19th. William Blair analyst S. Corwin now forecasts that the company will earn ($4.33) per share for the year, down from their previous forecast of ($4.31). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.45) per share. William Blair also issued estimates for Neurogene’s Q4 2024 earnings at ($1.04) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($4.32) EPS.

Several other analysts also recently issued reports on NGNE. Stifel Nicolaus lifted their price target on Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Robert W. Baird lifted their target price on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. BMO Capital Markets reduced their price target on Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday. Leerink Partners lifted their price objective on shares of Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Neurogene in a report on Tuesday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.83.

Neurogene Stock Up 30.2 %

NGNE opened at $20.30 on Thursday. Neurogene has a 12 month low of $12.49 and a 12 month high of $74.49. The firm’s fifty day simple moving average is $44.97 and its 200 day simple moving average is $39.53.

Hedge Funds Weigh In On Neurogene

Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP increased its position in Neurogene by 6.0% during the third quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock worth $47,635,000 after buying an additional 64,691 shares during the last quarter. FMR LLC raised its stake in Neurogene by 912.4% in the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after acquiring an additional 659,515 shares during the period. Vanguard Group Inc. lifted its holdings in Neurogene by 906.5% during the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after purchasing an additional 457,062 shares during the last quarter. Baker BROS. Advisors LP boosted its position in Neurogene by 0.6% during the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock worth $23,211,000 after purchasing an additional 2,499 shares during the period. Finally, State Street Corp increased its holdings in shares of Neurogene by 17.5% in the third quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after purchasing an additional 36,687 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.